About CaReMeLO
Cardiac disease, chronic kidney and liver disease and metabolic derangements like type 2 diabetes (T2DM) and their risk factors share etiologies and pathophysiologic mechanisms. These novel insights and their therapeutic implications have been recognized and adopted by cardiology, nephrology and endocrinology alike. Yet a need exists for a multidisciplinary scientific platform that unites all interested parties and serves as a unique gathering, devoting time to in-depth Cardiovascular, Renal, Liver, Metabolic and Obesity discussions.
This conference will continue to spotlight the pivotal role of family physicians in the integrated management of cardiometabolic, renal, liver and obesity syndromes (CaReMeLO), with enhanced focus on the latest GLP-1 RA therapies such as Tirzepatide (Mounjaro) and Semaglutide 2,4 mg (Wegovy).
Conference Highlights
Expanded Sessions
Dedicated tracks on the use of GLP-1 receptor agonists, highlighting their clinical benefits, patient selection, and real-world application in treating obesity.
Collaborative Workshops
Sessions on fostering a multidisciplinary approach to patient care, featuring insights into successful collaboration between family physicians, endocrinologists, cardiologists, nephrologists, and allied health professionals.
Expert Insights
Hear from a distinguished panel of speakers, as well as leading family physicians on cardiometabolic health and the role of the family physician.
Innovative Learning
Case-based discussions, interactive workshops, and hands-on training sessions designed to enhance practical skills.
Networking
Ample opportunities for one-on-one interactions, group discussions, and partnership development, with a focus on fostering collaborations that transcend national borders within Europe.
In partnership with the
Polish Society of Family Medicine (PTMR)
